ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$15.74
+3.01%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$15.42
From 52W high−5.18%
Volume156577.00
Market cap$1.01B
P/E (TTM)—
P/S (TTM)51.5x
Div yield—
Key dataSep 18, 2026
Open
$15.42
From 52W high
−5.18%
Volume
156577.00
Market cap
$1.01B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−37.6x
P/E (TTM)
—
RSI (14)
60.5
MomentumView details →
1D Return
+3.01%
YTD Return
+1015.49%
SummaryUpdated Jun 1, 2026
Adlai Nortye Ltd. (NASDAQ:ANL) is a clinical-stage biotechnology company founded in 2018 and incorporated in the Cayman Islands. The company went public in September 2023 and focuses on discovering and developing innovative cancer therapies for patients in the United States and Mainland China. As a relatively young biotech firm, Adlai Nortye is currently in the clinical development phase with its lead drug candidate progressing through Phase III trials, while maintaining a robust pipeline of preclinical and early-stage therapeutic programs targeting various cancer pathways.
Similar companies
Latest newsMore news →
Adlai Nortye dosed the first patient in Australia and received U.S. FDA IND clearance for AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC targeting CEACAM5, initiating a global Phase I trial.12d agoAdlai Nortye announced that it has submitted a clinical trial notification and received HREC approval to start a Phase I clinical trial of its pan-RAS(ON) inhibitor ADC AN4035 in Australia.48d ago